Hoth ends HT-001 skin-toxicity trial early, seeks FDA feedback on Phase 3

What happened

Rocket One Inc. said on 3 November 2026 that its biotechnology subsidiary, Hoth Therapeutics, ended the Phase 2a trial of HT-001 early after strong interim efficacy, and is preparing to ask the FDA for feedback on advancing the drug into a potential Phase 3 program ^[1]. HT-001 is a topical gel for the papulopustular skin eruptions that EGFR-inhibitor cancer therapy commonly causes ^[3][4]. The quantitative basis for "strong efficacy," response rate, lesion reduction, statistical threshold, is not in the release; the characterization is the company's own ^[1].

Why a skin-toxicity gel matters

EGFR inhibitors reliably produce an acne-like facial and truncal rash that can force dose reductions or treatment breaks in the underlying cancer. Supportive-care options are thin: topical corticosteroids and oral tetracyclines are the usual fallback, and a 2024 case report in the Journal of Drugs in Dermatology notes both are limited by side effects and by efficacy ^[4]. A topical agent that controls the rash without systemic exposure would let oncologists hold patients on full-dose EGFR therapy longer. That is the clinical wedge HT-001 is aiming at ^[3][4].

Read the corporate context before the data

The efficacy claim lands from a company that spent 2026 walking away from drug development. In May 2026, Hoth Therapeutics (Nasdaq: HOTH) changed its legal name to Rocket One Inc. and began trading as RKTO, repositioning the parent around AI, space and defense; the entire legacy pipeline, HT-001, HT-KIT, HT-ALZ and a GDNF metabolic program, was pushed into a wholly owned subsidiary ^[2]. A VP of R&D should weigh the 3 November statement against that backdrop: it is the clinical update on an asset the parent deprioritized months earlier, delivered as a wire release rather than a peer-reviewed dataset or a conference presentation ^[1][2].

What to watch

The pipeline had already telegraphed activity: the January 2026 investor deck listed a positive case-study result in Q3 2024, favorable interim clinical data in Q1 2025, an EU trial expansion submission targeted for Q3 2025 and a full PK dataset for Q1 2026 ^[3]. The next real catalyst is the FDA interaction itself. The company has stated intent to seek feedback, not a scheduled meeting, so there is no public target date for a Phase 3 go decision ^[1]. Watch for a standalone SEC 8-K carrying the topline numbers, an end-of-Phase-2 meeting outcome, and any registry entry for a Phase 3 protocol.

The now-what

For an operator with an EGFRi or supportive-care interest, three moves are on the table. Track the forthcoming 8-K and any FDA meeting minutes for the actual response data before assigning competitive weight; the "early stop for efficacy" framing is uncorroborated today. Map your own program's dermatologic-toxicity management against a topical aprepitant mechanism, since a validated non-steroidal option would reset the supportive-care baseline. And calibrate any partnering or in-licensing interest to the parent's commitment: an asset inside a subsidiary of a company now built around defense infrastructure may be available, or may be orphaned.

What Prognyx could not verify

No response rate, lesion-reduction figure or statistical detail behind "strong efficacy" is public, and the early-stop decision rests solely on the company's release ^[1]. Prognyx found no ClinicalTrials.gov registry record for the HT-001 Phase 2a trial, so its design, enrollment and current status cannot be independently confirmed. A September 2025 report attributed to Dermatology Digest said Hoth filed an EMA clinical trial application for a Phase 2 EU study; Prognyx could not confirm this from a primary EMA or company source ^[5]. No FDA meeting date or outcome is on the record ^[1].

Verdict: low immediate threat, an unquantified single-source efficacy claim from a deprioritized asset. The window to act opens only when the topline data and an FDA meeting outcome are public.